Limits...
Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems.

Vicente B, López-Abán J, Rojas-Caraballo J, del Olmo E, Fernández-Soto P, Muro A - Parasit Vectors (2016)

Bottom Line: In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60%, respectively), and hepatic lesions (45%).Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.Native FABP is more effective than both recombinant systems.

View Article: PubMed Central - PubMed

Affiliation: Parasite and Molecular Immunology Laboratory, Tropical Disease Research Centre, Universidad de Salamanca (IBSAL-CIETUS), Avda. Licenciado Méndez Nieto s/n, 37007, Salamanca, Spain.

ABSTRACT

Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection.

Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied.

Results: Vaccination with nFh12 induced significant reductions in worm burden (83%), eggs in tissues (82-92%) and hepatic lesions (85%) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64%), eggs in the liver (21-61%), eggs in the gut (30-77%) and hepatic damage (67-69%) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60%, respectively), and hepatic lesions (45%). We observed a significant rise in TNFα, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.

Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins.

No MeSH data available.


Related in: MedlinePlus

Antibody detection (IgG, IgG1, IgG2a, IgE and IgM) against rFh15 or rFh15b 2 weeks after immunisation schedule in BALB/c mice. Data presented as the mean ± standard error of the mean. Groups: Untreated; Treated with AA0029+Qs; Immunised with AA0029 + Qs + rFh15; and Immunised with AA0029+Qs+rFh15b. O.D., optical density; *P < 0.05 in comparison with untreated controls and treated with AA0029+Qs; †P < 0.05 compared to mice treated with AA0029+Qs+rFh15
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4836169&req=5

Fig5: Antibody detection (IgG, IgG1, IgG2a, IgE and IgM) against rFh15 or rFh15b 2 weeks after immunisation schedule in BALB/c mice. Data presented as the mean ± standard error of the mean. Groups: Untreated; Treated with AA0029+Qs; Immunised with AA0029 + Qs + rFh15; and Immunised with AA0029+Qs+rFh15b. O.D., optical density; *P < 0.05 in comparison with untreated controls and treated with AA0029+Qs; †P < 0.05 compared to mice treated with AA0029+Qs+rFh15

Mentions: Antibody response of rFh15- and rFh15b-immunised mice were studied to understand the intensity of the humoral response elicited by the two recombinant proteins, due to the importance of antibodies in resistance to schistosomiasis and in an attempt to explain the differential protection observed between these molecules. Two weeks after the immunisation schedule, a significantly higher production of specific IgG, IgG1, IgG2a, IgM, IgE anti-rFh15 or anti-rFh15b was observed in AA0029+Qs+rFh15 and in AA0029+Qs+rFh15b vaccinated mice respectively, compared to untreated controls (Fig. 5 and Additional file 3: Table S3). Furthermore, we observed significantly higher levels of IgG1 and IgM in mice vaccinated with rFh15 than mice vaccinated with rFh15b (Fig. 5 and Additional file 3: Table S3).Fig. 5


Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems.

Vicente B, López-Abán J, Rojas-Caraballo J, del Olmo E, Fernández-Soto P, Muro A - Parasit Vectors (2016)

Antibody detection (IgG, IgG1, IgG2a, IgE and IgM) against rFh15 or rFh15b 2 weeks after immunisation schedule in BALB/c mice. Data presented as the mean ± standard error of the mean. Groups: Untreated; Treated with AA0029+Qs; Immunised with AA0029 + Qs + rFh15; and Immunised with AA0029+Qs+rFh15b. O.D., optical density; *P < 0.05 in comparison with untreated controls and treated with AA0029+Qs; †P < 0.05 compared to mice treated with AA0029+Qs+rFh15
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4836169&req=5

Fig5: Antibody detection (IgG, IgG1, IgG2a, IgE and IgM) against rFh15 or rFh15b 2 weeks after immunisation schedule in BALB/c mice. Data presented as the mean ± standard error of the mean. Groups: Untreated; Treated with AA0029+Qs; Immunised with AA0029 + Qs + rFh15; and Immunised with AA0029+Qs+rFh15b. O.D., optical density; *P < 0.05 in comparison with untreated controls and treated with AA0029+Qs; †P < 0.05 compared to mice treated with AA0029+Qs+rFh15
Mentions: Antibody response of rFh15- and rFh15b-immunised mice were studied to understand the intensity of the humoral response elicited by the two recombinant proteins, due to the importance of antibodies in resistance to schistosomiasis and in an attempt to explain the differential protection observed between these molecules. Two weeks after the immunisation schedule, a significantly higher production of specific IgG, IgG1, IgG2a, IgM, IgE anti-rFh15 or anti-rFh15b was observed in AA0029+Qs+rFh15 and in AA0029+Qs+rFh15b vaccinated mice respectively, compared to untreated controls (Fig. 5 and Additional file 3: Table S3). Furthermore, we observed significantly higher levels of IgG1 and IgM in mice vaccinated with rFh15 than mice vaccinated with rFh15b (Fig. 5 and Additional file 3: Table S3).Fig. 5

Bottom Line: In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60%, respectively), and hepatic lesions (45%).Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.Native FABP is more effective than both recombinant systems.

View Article: PubMed Central - PubMed

Affiliation: Parasite and Molecular Immunology Laboratory, Tropical Disease Research Centre, Universidad de Salamanca (IBSAL-CIETUS), Avda. Licenciado Méndez Nieto s/n, 37007, Salamanca, Spain.

ABSTRACT

Background: Schistosomiasis is a water-borne disease afflicting over 261 million people in many areas of the developing countries with high morbidity and mortality. The control relies mainly on treatment with praziquantel. Fatty acid binding proteins (FABP) have demonstrated high levels of immune-protection against trematode infections. This study reports the immunoprotection induced by cross-reacting Fasciola hepatica FABP, native (nFh12) and recombinantly expressed using two different expression systems Escherichia coli (rFh15) and baculovirus (rFh15b) against Schistosoma mansoni infection.

Methods: BALB/c mice were vaccinated with native nFh12 or recombinant rFh15 and rFh15 FABP from F. hepatica formulated in adjuvant adaptation (ADAD) system with natural or chemical synthesised immunomodulators (PAL and AA0029) and then challenged with 150 cercariae of S. mansoni. Parasite burden, hepatic lesions and antibody response were studied in vaccination trials. Furthermore differences between rFh15 and rFh15b immunological responses (cytokine production, splenocyte population and antibody levels) were studied.

Results: Vaccination with nFh12 induced significant reductions in worm burden (83%), eggs in tissues (82-92%) and hepatic lesions (85%) compared to infected controls using PAL. Vaccination with rFh15 showed lower total worm burden (56-64%), eggs in the liver (21-61%), eggs in the gut (30-77%) and hepatic damage (67-69%) using PAL and AA0029 as immunomodulators. In contrast, mice vaccinated with rFh15b showed only reductions in eggs trapped in the liver and intestine (53 and 60%, respectively), and hepatic lesions (45%). We observed a significant rise in TNFα, IL-6, IL-2, IL-4 and high antibody response (IgG, IgG1, IgG2a, IgM and IgE) in mice immunised with either rFh15 or rFh15b. Moreover, mice immunised with rFh15b showed an increase in IFNγ and a decrease in B220 cells compared to untreated mice, and less production of IgG1 and IgM than in mice immunised by rFh15.

Conclusions: Higher level of protection is obtained by using Fasciola hepatica-derived FABP protein against Schistosoma mansoni infection. Native FABP is more effective than both recombinant systems. It could be due to post-translational modifications or FABP isoform or changes in the recombinant proteins.

No MeSH data available.


Related in: MedlinePlus